» Articles » PMID: 28289191

Cathepsin S is the Major Activator of the Psoriasis-associated Proinflammatory Cytokine IL-36γ

Overview
Specialty Science
Date 2017 Mar 15
PMID 28289191
Citations 68
Authors
Affiliations
Soon will be listed here.
Abstract

The proinflammatory cytokine IL-36γ is highly expressed in epithelial cells and is a pivotal mediator of epithelial inflammation. In particular, IL-36γ is strongly associated with the inflammatory skin disease psoriasis. As with other IL-1 cytokines, IL-36γ is expressed as an inactive precursor and must be processed by specific proteases to become bioactive. Our aim therefore was to identify protease/s capable of IL-36γ activation and explore the importance of this activation in psoriasis. Using a keratinocyte-based activity assay in conjunction with small-molecule inhibitors and siRNA gene silencing, cathepsin S was identified as the major IL-36γ-activating protease expressed by epithelial cells. Interestingly, cathepsin S activity was strongly up-regulated in samples extracted from psoriasis patients relative to healthy controls. In addition, IL-36γ-Ser18, identified as the main product of cathepsin S-dependent IL-36γ cleavage, induced psoriasiform changes in human skin-equivalent models. Together, these data provide important mechanistic insights into the activation of IL-36γ and highlight that cathepsin S-mediated activation of IL-36γ may be important in the development of numerous IL-36γ-driven pathologies, in addition to psoriasis.

Citing Articles

The complex roles of IL-36 and IL-38 in cancer: friends or foes?.

Finucane M, Brint E, Houston A Oncogene. 2025; .

PMID: 40057603 DOI: 10.1038/s41388-025-03293-4.


Deciphering the impact of aging on splenic endothelial cell heterogeneity and immunosenescence through single-cell RNA sequencing analysis.

Huang Y, Liu Z, Li M, Wang D, Ye J, Hu Q Immun Ageing. 2024; 21(1):48.

PMID: 39026350 PMC: 11256597. DOI: 10.1186/s12979-024-00452-1.


Inflammatory loop involving , IL-36γ, and cathepsin S drives immunity disorders in familial acne inversa keratinocytes.

Zhang Y, Jia W, Wang X, Mao Q, Luo L, Kong L Heliyon. 2024; 10(11):e31509.

PMID: 38947455 PMC: 11214400. DOI: 10.1016/j.heliyon.2024.e31509.


Targeting cathepsin S promotes activation of OLF1-BDNF/TrkB axis to enhance cognitive function.

Lee H, Chen S, Tsai K, Hsu K, Chen Y, Chang C J Biomed Sci. 2024; 31(1):46.

PMID: 38725007 PMC: 11084077. DOI: 10.1186/s12929-024-01037-2.


The role of dermal fibroblasts in autoimmune skin diseases.

Shi Z, Liu Z, Wei Y, Zhang R, Deng Y, Li D Front Immunol. 2024; 15:1379490.

PMID: 38545113 PMC: 10965632. DOI: 10.3389/fimmu.2024.1379490.


References
1.
Johnston A, Xing X, Guzman A, Riblett M, Loyd C, Ward N . IL-1F5, -F6, -F8, and -F9: a novel IL-1 family signaling system that is active in psoriasis and promotes keratinocyte antimicrobial peptide expression. J Immunol. 2011; 186(4):2613-22. PMC: 3074475. DOI: 10.4049/jimmunol.1003162. View

2.
Laws P, Young H . Current and emerging systemic treatment strategies for psoriasis. Drugs. 2012; 72(14):1867-80. DOI: 10.2165/11634980-000000000-00000. View

3.
Lopez-Castejon G, Brough D . Understanding the mechanism of IL-1β secretion. Cytokine Growth Factor Rev. 2011; 22(4):189-95. PMC: 3714593. DOI: 10.1016/j.cytogfr.2011.10.001. View

4.
Garlanda C, Dinarello C, Mantovani A . The interleukin-1 family: back to the future. Immunity. 2013; 39(6):1003-18. PMC: 3933951. DOI: 10.1016/j.immuni.2013.11.010. View

5.
Gabay C, Lamacchia C, Palmer G . IL-1 pathways in inflammation and human diseases. Nat Rev Rheumatol. 2010; 6(4):232-41. DOI: 10.1038/nrrheum.2010.4. View